• Acrivon Therapeutics granted stock options covering 111,150 common shares to one new employee under its 2023 Inducement Plan, with a grant date of May 15, 2026.
• Exercise price set at Nasdaq closing price for Acrivon shares on grant date.
• Vesting set at 25% on first anniversary of first day of month following employment start date, with remaining options vesting in 2.083% monthly installments, contingent on continued employment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acrivon Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605151600PRIMZONEFULLFEED9719891) on May 15, 2026, and is solely responsible for the information contained therein.